Key facts
- This page summarizes Shereen Solaiman's Form 4 filing for MYRIAD GENETICS INC (MYGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Nov 2026, 16:13.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
Footnote F2
The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.